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Available online 12 October 2013Painful diabetic peripheral neuropathy (DPN) is a common complication of diabetes and
the few approved therapies for the management of pain have limited efficacy and side
effects. With the aim to explore and develop new pharmacological treatments, we investigated
the antihyperalgesic properties of St. John's Wort (SJW) and feverfew in streptozotocin
(STZ)-diabetic rats. Acute administration of a SJW seed extract reversed mechanical
hyperalgesia with a prolonged effect. A SJW extract obtained from the aerial portion of
the plant and a feverfew flower extract partially relieved neuropathic pain whereas a
feverfew leaf extract was ineffective. The antihyperalgesic efficacy of these herbal drugs was
comparable to that of clinically used antihyperalgesic drugs (carbamazepine, lamotrigine,
L-acetyl-levocarnitine). Further examinations of SJW and feverfew composition revealed that
hyperforin and hypericin might be responsible for the antihyperalgesic properties of SJW
whereas the efficacy of feverfew seems to be related to the presence of parthenolide. Rats
undergoing treatment with SJW and feverfew did not show any behavioral side effect or sign
of altered locomotor activity. Our results suggest that SJW and feverfew extracts may become
new therapeutic perspectives for painful DPN.
© 2013 Elsevier B.V. All rights reserved.Keywords:
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Diabetic peripheral neuropathy (DPN) is the most prevalent
complication of diabetes. A population-based study reported
that more than half of diabetic patients develop DPN [1]. Of
these patients, 30 to 50% suffer from painful DPN, and chronic
pain associated with diabetes is represented by hyperalgesia,
allodynia, paresthesias, and spontaneous pain [2,3]. Although
neuropathy is a common symptom among diabetic patients, its
mechanisms remain unclear, and as a consequence, treatment
is unsatisfactory in many cases. Glycemic control has been
shown to be effective in slowing the progression of DPN [4], but
patients with painful DPN often need other agents to palliatences, Psychology, Drug
ni 6, I-50139 Florence,
tti).
ll rights reserved.their symptoms. Agents used include tricyclic antidepressants,
anticonvulsants, serotonin–norepinephrine reuptake inhibitors,
opiates, opiate-like substances and topical medications. How-
ever, these medications usually at best provide only partial
pain relief [5–7] and have severe side effects. Therefore, for an
effective treatment of neuropathic pain, there is still a need to
obtain therapeutics, which possess higher efficacy and a greater
level of tolerability and safety.
Hypericum perforatum L., commonly known as St. John's
Wort (SJW), is an herbal medicine known to have diverse
medicinal uses for centuries, including psychiatric disorders,
skin wounds, and inflammation. Numerous studies proved that
SJW is endowed with many bioactivities with a favorable side
effect profile. In addition to the well-documented antidepres-
sant efficacy [8], SJW also produced anti-inflammatory [9,10]
and analgesic effects [11,12].
Feverfew (Tanacetum parthenium L.), also known as
“medieval aspirin”, is a medicinal plant traditionally used as
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arthritis, stomach aches, toothaches, insect bites, infertility,
and menstrual disorders [13]. At the beginning of the 1980s,
feverfew gained attention for its apparent effectiveness in the
prophylaxis of migraine headaches. Several placebo con-
trolled clinical trials have shown feverfew to be an affective
oral agent in reducing the frequency and severity of migraine
headaches [14–17].
Due to the limited efficacy and tolerability of the
therapeutic options for painful DPN, we aimed to identify a
safer and effective treatment to manage pain in DPN. Based
on the analgesic activity of SJW and feverfew in pain of
various etiologies and on their elevated tolerability, we
investigated the efficacy of both herbal medicines in a rat
model of painful DPN. The most common SJW preparations
used are hydroalcoholic extracts of the aerial portion of the
plant that contain at least ten different kinds of biochemical
compounds, including hypericin and hyperforin [18]. The
dried leaves of feverfew contain a large number of natural
products, but the active principles probably include one or
more of the sesquiterpene lactones known to be present,
including parthenolide [19]. To better elucidate the pharma-
cological profile of SJW and feverfew and the role of their
main components, we compared the efficacy and phyto-
chemical composition of different dried extracts obtained
from SJW and feverfew.
2. Materials and methods
2.1. Feverfew and SJW extract preparation
Feverfew flowers and leaves, and SJW seed A were
collected from Tuscany cultivations. SJW seed B was obtained
from German cultivations. SJW seed, feverfew flower and leaf
extracts were made by Aboca SpA according to the condition
reported in Table 1. After 6–8 h, the EtOH/H2O herb/seed
mixture was dropped for 1 h and filtered to remove the
exhausted herb/seed. The corresponding hydroalcoholic ex-
tract was concentrated under vacuum to evaporate ethanol.
The water concentrate obtained underwent freeze-drying for
72 h and the resulting extracts were stored at 4 °C, protected
from light and humidity. Peculiar extraction conditions
(ethanol 70%) were chosen to extract the already known
metabolite of SJW, avoiding extraction of fat and waxes.
2.2. Feverfew and SJW extracts' fingerprint analysis
2.2.1. Sample preparation
2.2.1.1. Feverfew. Ethanol 50% (25 ml) was added to a sample
of the freeze-dried leaf, flower or seed extract (0.1 g). TheTable 1
Feverfew and St. John's Wort extraction conditions.
Extract Plant origin Ex
Feverfew flowers Collected from Tuscany cultivation Et
Feverfew leaves Collected from Tuscany cultivation Et
St. John's Wort seeds A Collected from Tuscany cultivation Et
St. John's Wort seeds B Purchased from the market — Germany Etresulting mixture was extracted in ultrasonic bath (20 min)
and then centrifuged (5 min at 4000 rpm). The supernatant
was then collected and the remaining solid material was
further extracted with ethanol 50% (25 ml) under the same
condition. After centrifugation the supernatant was added
to the supernatant previously collected, to achieve the
final volume of 50 ml. After filtration on cellulose acetate
(0.45 μm) the samples were used for the LC–MS analysis.
2.2.1.2. SJW. 0.25 g of the freeze-dried SJW seed extract was
weighed accurately and placed in a 50 ml volumetric tube.
Twenty milliliters of methanol was added and the tube was
sonicated for 30 min. The extract was centrifuged (5 min at
4000 rpm). The supernatant transferred into a 50 ml amber
volumetric flask. The residue re-extracted with 20 ml of the
same solvent. After centrifugation the supernatant was added
to the supernatant previously collected to the 50 ml amber
volumetric flask at 20 °C temperature and made up to
volume. Finally the extract was filtered on cellulose acetate
(0.45 μm). The samples were used for the LC/DAD analysis.
2.2.2. Instrumental conditions
The measurements were carried out by an Agilent 1100
LC–MSD trap system equipped with an ESI source and
consisting of a vacuum degasser, a binary pump, a Peltier
autosampler thermostated at 20 °C, and a Peltier column
compartment. The ESI parameters were the following:
Feverfew. [ESI(−)]: Dry temp 350 °C, nebulizer 40.0 psi,
dry gas 10.00 l/min, HV capillary 3500 V, skimmer−55.4 V,
capillary exit−140.2 V, lens 1 4.2 V, lens 2 46.9 V; [ESI(+)]
dry temp: 350 °C, nebulizer: 40.0 psi, dry gas: 10.00 l/min,
HV capillary: −3500 V, skimmer 55.4 V, capillary exit:
−140.2 V, lens 1: −4.2 V, lens 2: −46.9 V. The column
used was from Agilent Technologies Inc. (Palo Alto, CA;
poroshell RP-18, 3.0 mm × 100 mm, 100 Å, 2.7 μm).
The elution was performed with H20 0.1% HCOOH (solvent
A) and MeOH (solvent B). The gradient program used was:
0 min 90% A, 14 min 50% A, and 30 min 5% A. The flow rate
was 0.4 ml/min.
SJW. [ESI(−)]: Dry temp 350 °C, nebulizer 50.0 psi, dry
gas 10.00 l/min, HV capillary 3516 V, skimmer −33.1 V,
capillary exit −205.7 V, lens 1 3.8 V, lens 2 52.8 V. The
column used was from Phenomenex (Torrance, CA; Luna
RP-8, 4.60 mm × 150 mm, 100 Å, 5 μm). The elution was
performed with H20 0.1% HCOOH (solvent A) and CH3CN
(solvent B). The gradient program used was: 0 min 82% A,
8 min 82% A, 18 min 53% A, 18.10 min 97%, 38 min 97%
and 40 min 82%. The flow rate was 0.8 ml/min untiltraction solvent Drug/solvent ratio Extraction temperature
OH 50° 1/10 50 °C
OH 50° 1/13 50 °C
OH 70° 1/10 50 °C
OH 70° 1/10 50 °C
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volume is 10.00 μl.
2.3. Parthenolide analysis
2.3.1. Sample preparation
The HPLC analysis in leaf or flower feverfew extract was
performed according to the European Pharmacopoeia mono-
graph (VI Ed) reported for the feverfew aerial part. Methanol
(40 ml) was added to a sample of freeze-dried extract (0.5 g)
and the resulting mixture was extracted in a water-bath at
60 °C for 10 min and then filtered. The filter was rinsed with
further 40 ml of methanol in a water-bath at 60 °C for
10 min. After filtration the collected solution was evaporated
to dryness under reduced pressure. The residue was taken up
with methanol and diluted to 20 ml with the same solvent.
The resulting solution was diluted 1:2 before filtration on a
cellulose acetate filter (0.45 μm).
2.3.2. Instrumental conditions
The measures were carried out by an Agilent 1100 Series
LC/UV system consisting of a vacuum degasser, a quaternary
pump, a Peltier autosampler thermostated at 20 °C, a Peltier
column compartment thermostated at 20 °C, and a UV
detector. The column used was from Phenomenex (Torrance,
CA; Prodigy RP-18, 250 mm × 4.6 mm, 5 μm) and the elution
was performed with H2O (solvent A) and CH3CN (solvent B).
The gradient program used was: 0 min 60% A: 40% B, 25 min
60% A: 40% B, 25.1 min 40% A: 60% B, and 30 min 40% A: 60%
B. The flow rate was 1.0 ml/min. The detector UV/Vis was set
at 220 nm. Parthenolide was purchased from Sigma (P0667)
and dissolved in methanol 80%. The linearity of the method
was found between 0.05 and 0.5 mg/ml. The working
solutions were 0.066, 0.13, 0.26, and 0.52 mg/ml. The cor-
relation found was r = 0.999987. Each solution was injected
three times, the CV was inferior to 1%.
2.4. Hypericin and hyperforin analysis
2.4.1. Sample preparation
The HPLC analysis in seed SJW extract was performed
according to the following method. Methanol (25 ml) was
added to a sample of freeze-dried extract (0.5 g) and the
resulting mixture was extracted protected from the light in
an ultrasound bath at 35 °C for 30 min and then filtered in a
volumetric flask. The filter was rinsed with further 25 ml of
methanol and extracted again in the same conditions. After
filtration the collected solutions were brought to 50 ml. The
resulting solution was filtrated on a cellulose acetate filter
(0.45 μm) and used to perform HPLC analysis.
2.4.2. Hypericin assay instrumental conditions
The measures were carried out by an Agilent 1100 Series
LC/UV system consisting of a vacuum degasser, a quaternary
pump, a Peltier autosampler thermostated at 20 °C, a Peltier
column compartment thermostated at 20 °C, and a UV
detector. The column used was from Waters (Milford, MA;
Spherisorb ODS2, 250 mm × 4.6 mm, 5 μm) and the elution
was performed with SDS 10 mM solution, pH 2.5 controlled
with phosphoric acid (solvent A), and CH3CN (solvent B). Thegradient program used was: 0 min 25% A: 75% B, and 15 min
5% A: 95% B. The flow rate was 1.2 ml/min. The detector
UV/Vis was set at 590 nm. Hypericin (Sigma-Aldrich,
Milan, Italy) was dissolved in methanol/pyridine 18/2.
The linearity of the method was found between 0.06 and
0.3 mg/ml. The working solutions were 0.061, 0.122, and
0.244 mg/ml. The correlation found was r = 0.999966.
Each solution was injected three times; the CV was inferior
to 1%.2.4.3. Hyperforin assay instrumental conditions
The measures were carried out by an Agilent 1100 Series
LC/UV system consisting of a vacuum degasser, a quaternary
pump, a Peltier autosampler thermostated at 20 °C, a Peltier
column compartment thermostated at 20 °C, and a UV
detector. The column used was from Waters (Milford, MA;
Spherisorb ODS2, 250 mm × 4.6 mm, 5 μm) and the elution
was performed with H2O 0.2% phosphoric acid (solvent A),
CH3CN (solvent B), and CH3OH (solvent C). The gradient
program used was: 0 min 85% A: 15% B: 0% C, 10 min 70% A:
20% B: 10% C, and 20 min 15% A: 75% B: 10% C in isocratic
conditions till 45 min. The flow rate was 1.2 ml/min. The
detector UV/Vis was set at 270 nm. Hyperforin (Phytolab,
Italy) was dissolved in methanol/acetone 99.8/0.2. The linearity
of the method was found between 0.125 and 0.5 mg/ml. The
working solutions were 0.125, 0.25, and 0.5 mg/ml. The cor-
relation found was r = 0.999991. Each solution was injected
three times; the CV was inferior to 1%.2.5. Behavioral testing
Male Sprague–Dawley albino rats (180–200 g) from
Harlan (S. Piero al Natisone, Italy) were used. Four rats
were housed per cage. The cages were placed in the
experimental room 24 h before the test for acclimatization.
The animals were fed a standard laboratory diet and tap
water ad libitum and kept at 23 ± 1 °C. The rats had a 12-h
light/dark cycle, light at 7 AM. Animals were habituated to
the experimental room and were investigated by observers
blinded for treatment of the animals. All experiments were
carried out in accordance with the European Communities
Council Directive of 24 November 1986 (86/609/EEC). All
efforts were made to minimize animal suffering, and to
reduce the number of animals used.2.6. Production of diabetic neuropathy
Diabetes was induced by i.p. injection of streptozotocin
(STZ; Sigma-Aldrich, Milan, Italy) freshly dissolved in normal
saline at a dose of 50 mg/kg, administered the morning after
an overnight fast. Three days later glucose was measured by
reflectance photometry in tail vein blood and any STZ-treated
rats with blood glucose less than 270 mg/dl were rejected
from the study. Animals were then group-housed with full
access to food and water for 3 weeks and treatments were
given as defined below. All the animals were weekly
weighted and daily observed during the study. The experi-
ments were carried out on day 21.
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The instrument has a cone-shaped pusher and exerts a
force which is applied at a constant rate (32 g per second)
on the upper surface of the rat hind paw. The force is con-
tinuously monitored by a pointer which moves along a linear
scale. The pain threshold is given by the force which first
induces struggling from the rat. An arbitrary cut off value of
250 g was adopted. Those rats scoring less than 40 g or over
75 g in the pretest, performed before STZ administration, were
rejected (25%). The pain threshold of diabetic animals was
measured on day 21 and only hyperalgesic animals were
included in the study (50%).
2.8. Rotarod test
The apparatus consisted of a base platform and a rotating
rod of 3 cm diameter with a non-skid surface. The rod was
placed at a height of 29 cm from the base and the rod-
rotation speed was 4 rpm. The integrity of motor coordination
was assessed on the basis of the number of falls from the rod in
30 s, before and 15, 30, 45 and 60 min after the beginning of the
test.
2.9. Drug administration
The nociceptive threshold was evaluated 15, 30, 45 and
60 min after the beginning of the test. SJWand feverfewextracts,
and Remotive (standardized SJW dried extract containing 3%
hyperforin and 0.32% hypericins) (Aboca SpA, Sansepolcro, Italy)
were p.o. administered 30 min before the beginning of behav-
ioral tests, in correspondence to their maximum effect as
determined by time-course experiments.
Carbamazepine (20 mg/kg p.o.), lamotrigine (200 mg/kg
p.o.), phenobarbital (20 mg/kg p.o.) (Sigma, Milan, Italy) and
L-acetyl-levocarnitine (ALCAR, Sigma-Tau, Pomezia, Italy)
were used as antinociceptive reference drugs and employed
at the maximal doses unable to reduce spontaneous mobility.
ALCAR was administered at the dose of 30 or 100 mg/kg i.p.
twice daily for 14 days. Following reference drug adminis-
tration, the pain threshold was evaluated 30, 60, and 90 min
after injection.
2.10. Statistical analysis
The data used in statistical analysis was acquired from
eight animals for each group. All experimental results are
given as the mean ± S.E.M. One-way and two-way analyses
of variance, followed by Tukey and Bonferroni post hoc test,
respectively, were used for statistical analysis.
3. Results and discussion
3.1. Phytochemical analysis
3.1.1. Characterization of the SJW extracts: hypericin, hyperforin
content and fingerprint profile
The SJW seed extracts were evaluated by means of LC–UV
and LC–MS analyses. In Fig. 1 the relative amounts of
hypericins and hyperforins of the two seed extracts are
reported. The SJW seed A sample contains much morehypericins and hyperforins than the SJW seed B sample. The
hypericin quantitative data was referred to the sum of
hypericin and pseudohypericin, the hyperforin quantitative
data was the sum of hyperforin and adhyperforin.
The fingerprint profile of SJW seed extracts was
analyzed using a RP-HPLC–MS method and TIC chromato-
grams were recorded (Fig. 1). This analysis revealed quite
similar metabolic patterns for the SJW seed A (Fig. 1A) and
SJW seed B (Fig. 1B) extracts, with differences likely caused
by the abundance of the different phytochemical species.
The chromatogram reported in Fig. 1 also confirms the
hypothesis that SJW seed extract A is quite similar to SJW
flowerhead extracts (Fig. 1C), being present most of the
chemical species characteristic of SJW flowerhead extracts.
An additional fingerprint profile in Fig. 1D is reported to
capture visible profile at 590 nm characteristic of hypericins,
as it was not possible to see them on the TIC chromatogram.
The chromatographic profile confirms the quantitative data.
The use of a SJW seed extract seems intriguing, as it
should contain in potency all the metabolites expressed by
the mature plant individuals.
3.1.2. Characterization of the feverfew extracts: parthenolide
content and fingerprint profile
The parthenolide content and molecular fingerprint
profile of our feverfew extracts were evaluated by means of
LC–UV and LC–MS analyses. In Fig. 2 the relative amounts of
parthenolide of the two feverfew extracts are reported. The
flower extract contained much more parthenolide than the
leaf extract.
The fingerprint profile of feverfew extracts was analyzed
using the RP-HPLC–MS method and recording TIC chromato-
grams (Fig. 2). The compound identification was done by
means of MS/MS studies, comparison with internal MS
library and data reported in literature [13]. The analysis
revealed quite similar metabolic patterns for the two extracts,
with differences likely caused by the abundance of the
different phytochemical species. All the chromatograms
reported confirm that feverfew flower (Fig. 2A) and feverfew
leaf (Fig. 2B) extracts differ not only for the parthenolide
content but also for the amount of the compounds 3 and
4. Feverfew flower extract, even if endowed with a sim-
ilar profile to the leaf extract, differs in the abundance of
important constituents being enriched of the active constitu-
ent parthenolide and of compound 3 with retention time of
14.5 min (tri-caffeoylquinic acid).
The chemical structure of SJW and feverfew main
constituents is reported in Fig. 3.
3.2. Antihyperalgesic activity of SJW dried extract
Peripheral administration of STZ was used as a rat model
of painful diabetic neuropathy. In the paw pressure test,
obtained data clearly demonstrated a significant decrease in
the mechanical pain threshold of STZ-diabetic rats indicating
the occurrence of hyperalgesia. These findings are in agree-
ment with previous papers reporting on the mechanical
hyperalgesia of animals at early stages of experimental
diabetes [20,21]. A single oral administration of SJW seed
extract A dose-dependently (20–200 mg/kg) reversed the
mechanical hyperalgesia (Fig. 4A). The dose of 20 mg/kg was
Sample % Hypericins (p/p) % Hyperforins (p/p)
SJW seed extract A 0.11 0.6
SJW seed extract B 0.001 <LDQ (0,01)
A
B
C
Number RT MS1 MS2 Compound Comparison of relative abundance
Ion Polarity Parention BasePeack Secondarypeack
SJW seed
extract A
SJW seed
extract B
SJW flowerhead
reference extract  C
min m/z m/z m/z m/z 
1 11,2 neg 462,8 [M-H]- 300,7 Hyperoside +++ + +++
2 12,6 neg 476,8 [M-H]- 300,8 Quercetinglucoronide +++ + +++
3 14,7 neg 446,8 [M-H]- 300,8 Quercitroside +++ + +++
4 18,3 neg 300,9 [M-H]- 178,6 150,7 Quercetin ++ + +++
5 19,8 neg 536,9 [M-H]- 442,8 384,8 299,6 Biapigenin ++ + +++
6 24,5 neg 535,6 [M-H]- 466,0 Hyperforin +++ + +++
7 24,9 neg 549,6 [M-H]- 480,1 Adhyperforin +++ + +++
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7
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HypPseudoHyp
RT (min) Compound
5,6 (±0,2) PseudoHypericin
11,6 (±0,3) Hypericin
Fig. 1. LC–MS fingerprint chromatograms (TIC) for SJW seed extracts A (A) and B (B); Main constituents and corresponding MS data are shown. Hypericin and
hyperforin contents were reported.
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the rat pain threshold peaking at 120 mg/kg. At higher
concentrations, the antihyperalgesic effect diminished showinga bell-shaped trend (Fig. 4A). Time course experiments showed
the prolonged effect of SJW, being effective for 60 min
(Fig. 4B). Conversely, SJW seed extract B was ineffective
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Number Rt. Ion Polarity MS1 MS2 Compound
Parent ion Base Peack Secondary
Peack
TP flower
extract
TP leaf extract
min m/z m/z m/z 
1 9,5 neg 352,9 [M-H]- 190,7 178,7 Chlorogenic Acid isomer +++ +++
2 10,3 neg 352,9 [M-H]- 190,8 178,7 Chlorogenic Acid isomer +++ +++
3 14,5 neg 677,0 [M-H]- 514,9 352,9 tri-CaffeoylQuiniq Acid +++ +
4 14,8 neg 621,1 [M-H]- 351,1 269,2 Apigenin diglucuronide
isomer
+ +++
5 15,4 neg 514,9 [M-H]- 352,9 di-CaffeoylQuinic Acid
isomer
+++ +++
6 17,0 neg 514,9 [M-H]- 352,9 di-CaffeoylQuinic Acid
isomer
+++ +++
7 17,1 neg 444,8 [M-H]- 268,8 174,7 Apigenin glucuronide
isomer
+++ +++
8 21,8 pos 519,0 [2M+Na]+ 271,3  [M+Na]+ Parthenolide +++ +
Sample % parthenolide (p/p)
Feverfew flower extract 2.5
Feverfew leaf extract 0.38
Fig. 2. LC–MS fingerprint chromatograms (TIC) for feverfew flower (A) and leaf (B) extracts. Main constituents and corresponding MS data are shown.
Parthenolide content was indicated.
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neuropathic pain confirming our previous findings indicat-
ing the improving effect of SJW on nerve injury- and
chemotherapy-induced neuropathic pain models [12] and
extending the SJW antihyperalgesic efficacy to the diabetic
neuropathy.
The pharmacological efficacy of SJW in humans and
laboratory animals has been demonstrated by using SJW
dried extracts obtained from the aerial portion of the plant.
The activity of the seed extract A was, therefore, compared tothat exerted by a SJW aerial portion extract, Remotive,
that showed a partial reversal of mechanical hyperalgesia
(Fig. 4E) with a short-lasting effect (Fig. 4F). Our data
indicate that SJW seed extract A is a more effective than
seed extract B and Remotive in our experimental model,
which clarifies that not all extracts from the same plant
species exert the same pharmacological profile.
Antihyperalgesic effects of SJW on diabetic animals may
be related to the antidiabetic activity of the herbal drug. SJW
has been reported for its traditional use by diabetic patients
Compound Chemical structure 
Hypericin OH
O
O
OHOHOH
OH OH
Pseudohypericin OH
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O
O
OHOHOH
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O
O
O
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O
OH OH
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OR3 R1, R2, R3= 
O
(OH)OH
OH
Fig. 3. Chemical structure of SJW and feverfew main components.
29N. Galeotti et al. / Fitoterapia 92 (2014) 23–33and animal studies showed that repeated administration
of SJW for fourteen days induced antihyperglycemic effects
on STZ-diabetic rats [22,23]. On the other hand, restoration
of mechanical hyperalgesia observed in the present study
was obtained after a single administration of the extract,suggesting that the improvement of painful DPN may
probably be related to a direct antinociceptive activity of SJW.
The phytochemical composition of each extract was
analyzed in order to identify the compounds involved in the
antinociceptive activity. The SJW seed extracts investigated
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Fig. 4. Effect of SJW seed extracts on mechanical hyperalgesia in STZ-diabetic rats. (A) Dose–response (20–200 mg/kg) and (B) time-course (30 mg/kg) curves
for the antihyperalgesic effect of SJW dried extract A. (C) Dose–response (100–1000 mg/kg) and (D) time-course (600 mg/kg) curves for SJW dried extract B.
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antihyperalgesic and the extract B ineffective. Both extracts
showed a similar phytochemical profile, even if the active
constituents were more abundant in the extract A. In
particular, hyperforin was absent in the extract B and
hypericin was present at a concentration 100 times lower
than that found in the extract A. We have previously
demonstrated that both hyperforin and hypericin induced
antinociception [11] and antihypernociception [12]. We can,
hence, hypothesize that the antihyperalgesic activity of
the extract A might be related to the presence of both
phytochemicals. However Remotive only partially reduced
mechanical hyperalgesia. By comparing the phytochemical
compositions at the highest effective doses, Remotive
showed a slightly lower concentration of hypericin than
extract A and a 2 times higher hyperforin concentration.
On these bases we might propose a prominent role of
hypericin in the antihyperalgesic activity of the SJW seed
extract.Administration of drugs by oral gavage can be a stressful
procedure for the animal and currently it is not possible to
critically evaluate the extent to which some of the drug
effects observed might be due to stress-induced analgesia
associated with handling and injection of rats. An orally
administered vehicle group (CMC) was, therefore, included
in the study. A single p.o. administration of CMC did not alter
the pain threshold in comparison with the pre-treatment
values and did not show any antihyperalgesic activity in the
STZ-treated group (Fig. 4A).
3.3. Antihyperalgesic activity of feverfew dried extract
A single oral administration of the feverfew flower extract
prolonged the reduced response of diabetic animals, meaning
partial restoration of mechanical hyperalgesia. Feverfew
flower extract showed antihyperalgesic activity in the STZ
model, even if to a lesser extent to the SJW seed extract A. At
the dose of 1000 mg/kg partially reversed the mechanical
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centration was devoid of any effect (Fig. 5A). Time course
studies showed a short-lasting antihyperalgesic activity of
the extract (Fig. 5B). Conversely, the feverfew leave dried
extract was ineffective (Fig. 5C, D). Feverfew has been widely
used in indigenous medical practices for curing high fever,
headache, stomachache, toothache, rheumatoid arthritis,
menstrual irregularities, and other inflammatory diseases.
The anti-inflammatory properties of this herbal plant are related
to the NF-κB inhibiting activity of its main component,
parthenolide [24]. Feverfew also showed benefits in migraine
prophylaxis [17]. Here we extended the therapeutic applica-
tions of this herbal drug providing the first evidence for a
neuropathic pain relieving activity.
Similarly to the SJW seed extracts, also feverfew flower
and leaf extracts showed a similar phytochemical profile, butTable 2
Effect of carbamazepine, lamotrigine, and phenobarbital on hyperalgesia induced b
Pre-treatment Treatment (mg/kg p.o.) Mechanical thres
Before treatment
Saline Saline 62.3 ± 4.0
STZ Saline 35.7 ± 4.3
Saline Carbamazepine 20 61.6 ± 3.7
STZ Carbamazepine 20 32.9 ± 4.2
Saline Lamotrigine 200 63.8 ± 4.5
STZ Lamotrigine 200 31.5 ± 5.0
Saline Phenobarbital 20 59.7 ± 4.3
STZ Phenobarbital 20 31.7 ± 3.5
⁎ P b 0.05 versus STZ-treated rats.the flower extract differed in the abundance of the main
constituent, being enriched of parthenolide. Since the leaf
extract was ineffective, it appears that the presence of higher
concentrations of parthenolide is necessary to improve
nociception in STZ-diabetic rats.
3.4. Effect of anticonvulsant and neuroprotective drugs on
mechanical nociception
Anticonvulsant drugs (lamotrigine, carbamazepine) and
neuroprotective agents (ALCAR) are clinically used in the
diabetic neuropathy [25,26]. Carbamazepine showed the
highest efficacy since it was able to completely reverse the
mechanical hypernociception induced by STZ administration.
Lamotrigine partially antagonized nociceptive behavior. Pheno-
barbital, a non-analgesic anticonvulsant drug used as negativey STZ in the rat paw-pressure test.
hold (g)
After treatment
30 min 60 min 90 min
65.4 ± 5.5 62.2 ± 4.4 64.9 ± 5.1
33.6 ± 4.7 34.1 ± 5.1 30.8 ± 4.1
60.5 ± 4.9 60.8 ± 4.3 62.6 ± 4.9
58.5 ± 5.3⁎ 54.6 ± 6.4⁎ 39.4 ± 4.4
60.6 ± 4.3 63.3 ± 6.0 58.0 ± 5.6
50.3 ± 4.5⁎ 49.3 ± 5.2⁎ 38.4 ± 4.0
58.4 ± 6.3 66.2 ± 6.1 62.5 ± 5.0
30.7 ± 4.7 35.7 ± 4.5 37.3 ± 5.3
Table 3
Effect of ALCAR on hyperalgesia induced by STZ in the rat paw-pressure test.
Pre-treatment Treatment (mg/kg i.p.) Mechanical threshold (g)
Before the last injection of ALCAR After the last injection of ALCAR
30 min 45 min 60 min
Saline Saline 60.4 ± 4.4 65.5 ± 5.7 61.3 ± 4.9 64.5 ± 5.1
STZ Saline 41.1 ± 4.8 39.6 ± 6.2 36.4 ± 4.3 37.6 ± 4.9
Saline ALCAR 30 69.3 ± 5.0 72.8 ± 4.5 70.5 ± 3.7 68.9 ± 5.0
STZ ALCAR 30 42.4 ± 4.3 43.6 ± 5.4 39.3 ± 4.6 38.7 ± 5.5
Saline ALCAR 100 147.3 ± 6.2§ 151.8 ± 6.6§ 155.0 ± 7.4§ 148.7 ± 7.1§
STZ ALCAR 100 69.4 ± 4.5⁎ 72.9 ± 5.5⁎ 77.5 ± 6.3⁎ 73.9 ± 6.4⁎
ALCAR was administered twice daily for 14 days.
⁎ P b 0.05 versus STZ-treated rats.
§ P b 0.05 versus saline-treated rats.
32 N. Galeotti et al. / Fitoterapia 92 (2014) 23–33control, was ineffective. Anticonvulsants were all unable to
increase the pain threshold in non-diabetic control mice
(Table 2).
ALCAR showed antihyperalgesic efficacy at a dose
(100 mg/kg) able to increase the pain threshold in saline-
treated control animals. Conversely, at a non-analgesic
lower dose (30 mg/kg) was devoid of any effect (Table 3).
The intensity of the antihyperalgesic effect of the seed
extract A was comparable to that produced by drugs clinically
used in the treatment of painful DPN, such as the anticon-
vulsant drug carbamazepine and the neuroprotective agent
ALCAR. While the flower extract showed a lower efficacy
than the SJW seed extract, the intensity of the feverfew effect
was comparable to that produced by lamotrigine.
3.5. Lack of effect of SJW and feverfew extracts on rat locomotor
behavior
An important drawback of the current analgesic therapy
of DPN is the high occurrence of side effects. The potential
induction of side effects by SJW and feverfew extracts was,
therefore, investigated. Both herbal drugs did not show any
alteration of the rats' gross behavior. Furthermore, the SJW
and feverfew extracts were tested, at the highest effective
concentrations, to assess their effect on motor coordination
by use of the rotarod test. The number of falls from the
rotating rod of rats orally pretreated with the above-
mentioned extracts was comparable to the control group,
showing the lack of any motor impairment. Each group
progressively reduced the number of falls because mice
learned how to balance on the rotating rod (Table 4). Present
results are in accordance with literature data that indicate
SJW [27] and feverfew [28] as medicinal plants with a
favorable tolerability and safety profile.Table 4
Lack of locomotor impairment by SJW seed A and feverfew flower extracts in
the rotarod test.
Treatment Number of falls in 30 s
Before
treatment
After treatment
15 min 30 min 45 min 60 min
Saline 5.9 ± 0.6 4.5 ± 0.5 2.1 ± 0.5 2.0 ± 0.5 1.3 ± 0.6
SJW seed A 5.5 ± 0.3 4.2 ± 0.7 2.7 ± 0.5 2.2 ± 0.5 1.5 ± 0.3
Feverfew FLW 6.0 ± 0.5 4.7 ± 0.7 2.5 ± 0.5 2.2 ± 0.5 1.9 ± 0.44. Conclusion
Present results exhibited for the first time the capability of
a single oral administration of a SJW seed extract and
feverfew flower extract for improvement of the mechanical
hyperalgesia developed in STZ-diabetic rats. These herbal
drugs showed a good efficacy along with a favorable safety
profile. These findings suggest these plants as a new drug
candidate/source for the treatment of diabetic pain.
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